Edgewise Therapeutics Inc EWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
-
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
-
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
Edgewise Shares Rise Premarket on FDA Fast-Track Designation
-
Edgewise Gets FDA Orphan, Rare-Pediatric-Disease Designations for Muscular-Dystrophy Program
Trading Information
- Previous Close Price
- $25.99
- Day Range
- $25.65–26.91
- 52-Week Range
- $5.12–30.00
- Bid/Ask
- $26.09 / $26.09
- Market Cap
- $2.45 Bil
- Volume/Avg
- 769,039 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 97
- Website
- https://www.edgewisetx.com
Comparables
Valuation
|
Metric
|
EWTX
|
TERN
|
CTNM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.79 | 2.75 | 2.23 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
EWTX
TERN
CTNM
Financial Strength
|
Metric
|
EWTX
|
TERN
|
CTNM
|
|---|---|---|---|
Quick Ratio | 29.79 | 20.57 | 58.48 |
Current Ratio | 30.24 | 21.02 | 58.92 |
Interest Coverage | — | — | — |
Quick Ratio
EWTX
TERN
CTNM
Profitability
|
Metric
|
EWTX
|
TERN
|
CTNM
|
|---|---|---|---|
Return on Assets (Normalized) | −23.23% | −28.87% | −18.15% |
Return on Equity (Normalized) | −24.43% | −30.36% | −871.68% |
Return on Invested Capital (Normalized) | −29.19% | −34.37% | −892.99% |
Return on Assets
EWTX
TERN
CTNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mnqgtntnk | Mhzlf | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xvssrbdcs | Mwsmx | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nzmpwcdt | Bgfkgv | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ytkkhvvt | Rthrtn | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Rsfrdyyn | Mpws | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ncmnrbr | Ryvj | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ctbnzpzfc | Bcnt | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Mnbkxrycq | Htkdt | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ydjkqcpzj | Pjflzj | $13.4 Bil | |||
| Incyte Corp
INCY
| Nmkdycdk | Wwkmng | $12.7 Bil |
United States